GeneStrat blood-based mutation testing for advanced lung cancer offers significant advantages for patients and their treating physicians over standard tissue testing, which can delay treatment.
Biodesix to Present Data on Blood Based Diagnostic Tests for Patients with Non-Small Cell Lung Cancer (NSCLC)
Biodesix data on proteomic and genomic blood-based assays presented at EORTC
Investigational Blood Test Identifies Patients with Melanoma Who Are More Likely to Have Improved Survival on Nivolumab Therapy; Biodesix’ blood test is independent of PD-L1 expression
Investigational blood test identifies patients with melanoma who are more likely to have improved survival on Nivolumab therapy.
VeriStrat and Epidermal Growth Factor Receptor Mutation Status Study Results Presented at 16th World Conference On Lung Cancer
VeriStrat and Epidermal Growth Factor Receptor Mutation Status Study results presented at 16th World Conference on Lung Cancer
Biodesix named to Inc. 500|5000 Fastest-Growing Private Companies list
Biodesix Adds Biognosys’ Proteomics Technology To Its Diagnostic Development Capabilities; Collaboration Enables Protein Identification Within Proteomic Signatures
Biodesix recently added Biognosys' Proteomics to their capabiltites.
HealthNet now covers Biodesix' VeriStrat test
Biodesix raises follow-on series E financing
Biodesix announced that the VeriStrat® test is now considered a medically necessary benefit by Aetna Corporation.
Biodesix' VeriStrat test is covered by Cigna